Advertisement

Superiority of Fondaparinux Over Enoxaparin in Preventing Venous Thromboembolism in Major Orthopedic Surgery Using Different Efficacy End Points

      Study objectives:

      To assess the relevance of various efficacy end points established for thromboprophylaxis trials, we compared the results of the fondaparinux phase III program in major orthopedic surgery using the original primary efficacy end point with those obtained when the efficacy end points recently suggested by the American College of Chest Physicians (ACCP) Consensus Conference on Antithrombotic Therapy and the European Committee for Proprietary Medicinal Products (CPMP) were used.

      Setting and patients:

      Fondaparinux was compared with enoxaparin in four multicenter, randomized, double-blind trials of major orthopedic surgery. The original primary efficacy end point consisted of a composite of deep-vein thrombosis detected by mandatory bilateral venography, documented symptomatic deep-vein thrombosis, or pulmonary embolism up to day 11. The efficacy end point established by the ACCP Consensus Conference on Antithrombotic Therapy comprises any proximal deep-vein thrombosis, symptomatic proven deep-vein thrombosis or pulmonary embolism, or fatal pulmonary embolism, and that established by the European CPMP comprises any proximal deep-vein thrombosis, symptomatic proven pulmonary embolism, or death from any cause.

      Interventions:

      Patients were randomized to receive either subcutaneous fondaparinux (2.5 mg once daily) starting postoperatively or approved enoxaparin regimens.

      Results:

      Using the original end point of the fondaparinux studies, the incidence of venous thromboembolism was 13.7% (371 of 2,703 patients) in the enoxaparin group compared with 6.8% (182 of 2,682 patients) in the fondaparinux group, with a common odds reduction of 55.2% (p = 10−17; 95% confidence interval, 45.8% to 63.1%) in favor of fondaparinux. The respective incidences of efficacy end points with enoxaparin and fondaparinux were 3.3% and 1.7%, respectively, according to the ACCP definition, and 3.9% and 2.1%, respectively, according to the CPMP definition. The common odds reduction in favor of fondaparinux was 49.6% (p < 0.001) and 48.0% (p < 0.001), respectively.

      Conclusions:

      Fondaparinux was consistently more effective than enoxaparin in preventing venous thromboembolism in patients undergoing major orthopedic surgery, irrespective of the established composite outcomes used.

      Key words

      Abbreviations:

      ACCP (American College of Chest Physicians), CI (confidence interval), CPMP (Committee for Proprietary Medicinal Products)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to CHEST
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Geerts WH
        • Heit JA
        • Clagett GP
        • et al.
        Prevention of venous thromboembolism: Sixth ACCP Consensus Conference on Antithrombotic Therapy.
        Chest. 2001; 119: 132S-175S
        • Kearon C
        • Julian JA
        • Math M
        • et al.
        Noninvasive diagnosis of deep venous thrombosis.
        Ann Intern Med. 1998; 128: 663-677
        • Warwick D
        • Williams MH
        • Bannister GC
        Death and thromboembolic disease after total hip replacement: a series of 1162 cases with no routine chemical prophylaxis.
        J Bone Joint Surg Br. 1973; 77: 6-10
        • Davidson BL
        What are the most reliable detection methods for deep vein thrombosis and pulmonary embolism to be used as endpoints in trials of venous thromboprophylaxis.
        Haemostasis. 1998; 28: 113-119
        • Committee for Proprietary Medicinal Products
        Points to consider on clinical investigation of medicinal products for prophylaxis of intra- and postoperative venous thromboembolic risk: The European Agency for the Evaluation of Medicinal Products. The European Agency for the Evaluation of Medicinal Products, London, UK2000 (CPMP/EWP/707/98)
        • Eriksson BI
        • Bauer KA
        • Lassen MR
        • et al.
        Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.
        N Engl J Med. 2001; 345: 1298-1304
        • Bauer KA
        • Eriksson BI
        • Lassen MR
        • et al.
        Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.
        N Engl J Med. 2001; 345: 1305-1310
        • Lassen MR
        • Bauer KA
        • Eriksson BI
        • et al.
        Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison.
        Lancet. 2002; 359: 1715-1720
        • Turpie AGG
        • Bauer KA
        • Eriksson BI
        • et al.
        Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial.
        Lancet. 2002; 359: 1721-1726
        • Turpie AGG
        • Bauer KA
        • Eriksson BI
        • et al.
        Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.
        Arch Intern Med. 2002; 162: 1833-1840
        • Rabinov K
        • Paulin S
        Roentgen diagnosis of venous thrombosis in the leg.
        Arch Surg. 1972; 104: 134-144
        • The PIOPED Investigators
        Value of the ventilation/perfusion scan in acute pulmonary embolism: results of the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED).
        JAMA. 1990; 263: 2753-2759
        • Nicolaides AN
        • Breddin HK
        • Fareed J
        • et al.
        Prevention of venous thromboembolism: International Consensus Statement; guidelines compiled in accordance with the scientific evidence.
        Int Angiol. 2001; 20: 1-37
        • Douketis JD
        • Eikelboom JW
        • Quinlan DJ
        • et al.
        Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes.
        Arch Intern Med. 2002; 162: 1465-1471
        • Girard P
        • Musset D
        • Parent F
        • et al.
        High prevalence of detectable venous thrombosis in patients with acute pulmonary embolism.
        Chest. 1999; 116: 903-908
        • Collins R
        • Scrimgeour A
        • Yusuf S
        • et al.
        Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic, and urologic surgery.
        N Engl J Med. 1988; 318: 1162-1173
        • Leizorovicz A
        • Haugh MC
        • Chapuis F-R
        • et al.
        Low molecular weight heparin in prevention of postoperative thrombosis.
        BMJ. 1992; 305: 913-920
        • Nurmohamed MT
        • Rosendaal FR
        • Büller HR
        • et al.
        Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery.
        Lancet. 1992; 340: 152-156
        • Mismetti P
        • Laporte-Simitsidis S
        • Tardy B
        • et al.
        Prophylaxis of post-operative venous thrombosis and pulmonary embolism by oral anticoagulants: a meta-analysis.
        Clin Trials Meta-anal. 1993; 28: 227-240
        • Mismetti P
        • Laporte-Simitsidis S
        • Tardy B
        • et al.
        Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials.
        Thromb Haemost. 2000; 83: 14-19
        • Mismetti P
        • Laporte S
        • Darmon JY
        • et al.
        Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery.
        Br J Surg. 2001; 88: 913-930
        • Eriksson BI
        • Ekman S
        • Kälebo P
        • et al.
        Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393.
        Lancet. 1996; 347: 635-639
        • Eriksson BI
        • Wille-Jorgensen P
        • Kälebo P
        • et al.
        A comparison of recombinant hirudin with low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement.
        N Engl J Med. 1997; 337: 1329-1335
        • Kakkar VV
        • Howe CT
        • Flanc C
        • et al.
        Natural history of postoperative deep-vein thrombosis.
        Lancet. 1969; 2: 230-232
        • Doyle DJ
        • Turpie AG
        • Hirsh J
        • et al.
        Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis: a randomized trial.
        Ann Intern Med. 1987; 107: 441-445
        • Saeger W
        • Genzkow M
        Venous thromboses and pulmonary embolisms in post-mortem series: probable causes by correlations of clinical data and basic diseases.
        Pathol Res Pract. 1994; 190: 394-399
        • Lagerstedt CI
        • Olsson CG
        • Fagher BO
        • et al.
        Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis.
        Lancet. 1985; 2: 515-518
        • Keller F
        • Flosbach CW
        • PRIME Study Group
        • et al.
        A randomized multicenter study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilized medical patients.
        Thromb Haemost. 1995; 73 ([abstract]): 1106
        • Harenberg J
        • Roebruck P
        • Heene DL
        Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients: the Heparin Study in Internal Medicine Group.
        Haemostasis. 1996; 26: 127-139
        • Wells PS
        • Lensing AWA
        • Davidson BL
        • et al.
        Accuracy of ultrasound for the diagnosis of deep venous thrombosis in asymptomatic patients after orthopedic surgery: a meta-analysis.
        Ann Intern Med. 1995; 122: 47-53
        • Davidson BL
        • Elliot CG
        • Lensing AWA
        Low accuracy of color Doppler ultrasound in the detection of proximal leg vein thrombosis in asymptomatic high-risk patients.
        Ann Intern Med. 1992; 117: 735-738
        • Agnelli G
        • Cosni B
        • Ranucci V
        • et al.
        Impedance plethysmography in the diagnosis of asymptomatic deep vein thrombosis in hip surgery.
        Arch Intern Med. 1991; 151: 2167-2171
        • Jongbloets LMM
        • Lensing AWA
        • Koopman MMW
        • et al.
        Limitations of compression ultrasound for the detection of symptomless postoperative deep vein thrombosis.
        Lancet. 1994; 343: 1142-1144
        • Fraser DGW
        • Moody AR
        • Morgan PS
        • et al.
        Diagnosis of lower-limb deep venous thrombosis: a prospective blinded study of magnetic resonance direct thrombus imaging.
        Ann Intern Med. 2002; 136: 89-98
        • Turpie AGG
        • Gallus AS
        • Hoek JA
        A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement: the Pentasaccharide Investigators.
        N Engl J Med. 2001; 344: 619-625